Keyphrases
Ponatinib
100%
Pityriasis Rubra pilaris
100%
Ichthyosiform
100%
Chemotherapy
33%
Cutaneous Eruption
33%
Older Women
16%
Malignancy
16%
Targeted Therapy
16%
Tyrosine Kinase Inhibitor
16%
Conventional Chemotherapy
16%
Third Generation
16%
Chronic Myeloid Leukemia
16%
Plaque
16%
Interferon-α (IFN-α)
16%
Imatinib
16%
Dasatinib
16%
Thigh
16%
50 Years Old
16%
Abdomen
16%
Cheek
16%
Systemic Side Effects
16%
Perivascular Fibrosis
16%
Skin Biopsy
16%
Axilla
16%
Forehead
16%
Bosutinib
16%
Dermatological Diseases
16%
Parakeratosis
16%
Lymphocyte Infiltration
16%
Drug Reaction
16%
Cutaneous Toxicity
16%
Orthokeratosis
16%
Retinoid Therapy
16%
Topical Tretinoin
16%
Third-generation Tyrosine Kinase Inhibitor
16%
Medicine and Dentistry
Ponatinib
100%
Pityriasis Rubra Pilaris
100%
Chemotherapy
50%
Tyrosine-Kinase Inhibitor
33%
Disease
16%
Cancer
16%
Targeted Therapy
16%
Adverse Event
16%
Retinoid
16%
Chronic Myelogenous Leukemia
16%
Imatinib
16%
Fibrosis
16%
Tretinoin
16%
Axilla
16%
Skin Biopsy
16%
Cheek
16%
Bosutinib
16%
Drug Hypersensitivity
16%
Dermatological Agent
16%
Skin Toxicity
16%
Parakeratosis
16%
Interferon
16%
Dasatinib
16%
Thigh
16%